MX2022007624A - Combinaciones. - Google Patents

Combinaciones.

Info

Publication number
MX2022007624A
MX2022007624A MX2022007624A MX2022007624A MX2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A
Authority
MX
Mexico
Prior art keywords
combinations
disease
treating
compounds
condition
Prior art date
Application number
MX2022007624A
Other languages
English (en)
Inventor
Kevin Duane Bunker
Fernando Donate
Peter Qinhua Huang
Ahmed Abdi Samatar
Jiali Li
Jianhui Ma
Sayee Gajanan Hegde
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2022007624A publication Critical patent/MX2022007624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)

Abstract

En la presente descripción se describen combinaciones de compuestos para tratar una enfermedad o afección, tal como el cáncer. Una combinación de compuestos para tratar una enfermedad o afección puede incluir un inhibidor de SERD y un inhibidor de WEE1, junto con sales farmacéuticamente aceptables de cualquiera de los anteriores.
MX2022007624A 2019-12-20 2020-12-16 Combinaciones. MX2022007624A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952042P 2019-12-20 2019-12-20
US202063009754P 2020-04-14 2020-04-14
PCT/US2020/065411 WO2021127046A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
MX2022007624A true MX2022007624A (es) 2022-08-16

Family

ID=76478099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007624A MX2022007624A (es) 2019-12-20 2020-12-16 Combinaciones.

Country Status (12)

Country Link
US (1) US20230042653A1 (es)
EP (1) EP4069224A4 (es)
JP (1) JP2023507799A (es)
KR (1) KR20220119428A (es)
CN (1) CN115103673A (es)
AU (1) AU2020408698A1 (es)
BR (1) BR112022012286A2 (es)
CA (1) CA3165477A1 (es)
IL (1) IL294084A (es)
MX (1) MX2022007624A (es)
TW (1) TW202135810A (es)
WO (1) WO2021127046A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198281B2 (en) * 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
US8703779B2 (en) * 2009-09-15 2014-04-22 Merck Sharp & Dohme Corp. Preparation of crystalline forms of dihydropyrazolopyrimidinone
JP6290237B2 (ja) * 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための組成物および方法
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
CN112679495B (zh) * 2016-04-01 2023-03-28 里科瑞尔姆Ip控股有限责任公司 雌激素受体调节剂
CN111344290B (zh) * 2017-11-01 2023-12-01 无锡智康弘义生物科技有限公司 作为Wee1抑制剂的大环类化合物及其应用

Also Published As

Publication number Publication date
US20230042653A1 (en) 2023-02-09
IL294084A (en) 2022-08-01
CN115103673A (zh) 2022-09-23
BR112022012286A2 (pt) 2022-08-30
CA3165477A1 (en) 2021-06-24
WO2021127046A1 (en) 2021-06-24
KR20220119428A (ko) 2022-08-29
AU2020408698A1 (en) 2022-07-14
TW202135810A (zh) 2021-10-01
EP4069224A1 (en) 2022-10-12
JP2023507799A (ja) 2023-02-27
EP4069224A4 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2022007628A (es) Combinaciones.
MX2022007626A (es) Combinaciones.
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
CA2983481A1 (en) Janus kinase inhibitor
MX2023008954A (es) Inhibidores de los receptores erbb.
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
PH12021550124A1 (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
TW200640883A (en) Compounds for the treatment of proliferative disorders
EA202193015A1 (ru) Ингибиторы cdk
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
TW200716570A (en) Compounds for the treatment of proliferative disorders
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2021010321A (es) Compuestos macrociclicos.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
GEP20247627B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
MX2022007623A (es) Combinaciones.
CO2017009182A2 (es) Cepas bacterianas productoras de histamina para tratamiento del cáncer
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
MX2022007625A (es) Combinaciones.
MX2021009717A (es) Sulfonamidas biciclicas.